The direct costs of treating human visceral leishmaniasis in Brazil

Detalhes bibliográficos
Autor(a) principal: Assis, Tália Santana Machado de
Data de Publicação: 2017
Outros Autores: Rosa, Dian Carlos Pinheiro, Teixeira, Eliane de Morais, Cota, Gláucia Fernandes, Silva, André Luís Ferreira Azeredo da, Werneck, Guilherme, Rabello, Ana Lucia Teles
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/29297
Resumo: Fundação Oswaldo Cruz. Instituto René Rachou. Pesquisa Clínica e Políticas Públicas em Doenças Infecciosas e Parasitárias. Belo Horizonte, MG, Brasil/Centro Federal de Educação Tecnológica de Minas Gerais. Contagem, MG, Brasil.
id CRUZ_787c741acba74ad50113d92087994bbf
oai_identifier_str oai:www.arca.fiocruz.br:icict/29297
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Assis, Tália Santana Machado deRosa, Dian Carlos PinheiroTeixeira, Eliane de MoraisCota, Gláucia FernandesSilva, André Luís Ferreira Azeredo daWerneck, GuilhermeRabello, Ana Lucia Teles2018-10-03T16:59:08Z2018-10-03T16:59:08Z2017ASSIS, Tália Santana Machado de et al. The direct costs of treating human visceral leishmaniasis in Brazil. Rev. Soc. Bras. Med. Trop., v. 50, n. 4, p. 478-482, 20170037-8682https://www.arca.fiocruz.br/handle/icict/2929710.1590/0037-8682-0133-2017engSociedade Brasileira de Medicina Tropicalterapeuticascustosanalise de custosleishmaniose visceralTherapeuticsCosts;; Cost analysisVisceral leishmaniasisThe direct costs of treating human visceral leishmaniasis in Brazilinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleFundação Oswaldo Cruz. Instituto René Rachou. Pesquisa Clínica e Políticas Públicas em Doenças Infecciosas e Parasitárias. Belo Horizonte, MG, Brasil/Centro Federal de Educação Tecnológica de Minas Gerais. Contagem, MG, Brasil.Fundação Oswaldo Cruz. Instituto René Rachou. Pesquisa Clínica e Políticas Públicas em Doenças Infecciosas e Parasitárias. Belo Horizonte, MG, BrasilFundação Oswaldo Cruz. Instituto René Rachou. Pesquisa Clínica e Políticas Públicas em Doenças Infecciosas e Parasitárias. Belo Horizonte, MG, BrasilFundação Oswaldo Cruz. Instituto René Rachou. Pesquisa Clínica e Políticas Públicas em Doenças Infecciosas e Parasitárias. Belo Horizonte, MG, BrasilInstituto de Avaliação de Tecnologia em Saúde. Porto Alegre, RS, Brasil/Universidade Federal do Rio Grande do Sul. Porto Alegre, RS, Brasil.Universidade do Estado do Rio de Janeiro. Instituto de Medicina Social. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto René Rachou. Pesquisa Clínica e Políticas Públicas em Doenças Infecciosas e Parasitárias. Belo Horizonte, MG, Brasil.INTRODUCTION: The drugs available for visceral leishmaniasis (VL) treatment in Brazil have specific characteristics in terms of operability, effectiveness, toxicity, and cost. The aim of this study was to estimate the direct costs of therapies recommended by the Ministry of Health (MH) for VL treatment in Brazil. METHODS: The analytical perspective used was that adopted by the Brazilian Public Health System. Three drugs and four regimens were included: 1) N-methyl glucamine antimoniate intramuscularly at 20mg per kg per day for 30 days; 2) N-methyl glucamine antimoniate intravenously at 20mg per kg per day for 30 days; 3) amphotericin B deoxycholate at 1mg per kg per day for 21 days; and 4) liposomal amphotericin B at 3mg per kg per day for a 7 days treatment. RESULTS: The estimated direct costs of treatment for an adult patient using N-methylglucamine antimoniate administered via the intramuscular and intravenous routes were USD 418.52 and USD 669.40, respectively. The estimated cost of treatment with amphotericin B deoxycholate was USD 1,522.70. Finally, the estimated costs of treatment with liposomal amphotericin B were USD 659.79, and USD 11,559.15 using the price adopted by the WHO and the Drug Regulation Board, respectively. CONCLUSIONS: This analysis indicates the economic feasibility of replacing N-methyl glucamine antimoniate with liposomal amphotericin B, which allows a shorter treatment period with less toxicity compared with other treatments, provided that the purchase value used by the WHO and transferred to the MH is maintained.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83082https://www.arca.fiocruz.br/bitstream/icict/29297/1/license.txt9193a7c197bc67acd023525e72a03240MD51ORIGINALThe direct costs of treating human visceral.pdfThe direct costs of treating human visceral.pdfapplication/pdf380634https://www.arca.fiocruz.br/bitstream/icict/29297/2/The%20direct%20costs%20of%20treating%20human%20visceral.pdf70e43e776f164ae3ba77aa88ecd076c4MD52TEXTThe direct costs of treating human visceral.pdf.txtThe direct costs of treating human visceral.pdf.txtExtracted texttext/plain27008https://www.arca.fiocruz.br/bitstream/icict/29297/3/The%20direct%20costs%20of%20treating%20human%20visceral.pdf.txtfef71bc1db09bcf4c61eae183cf30b34MD53icict/292972019-06-19 10:11:58.082oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352019-06-19T13:11:58Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv The direct costs of treating human visceral leishmaniasis in Brazil
title The direct costs of treating human visceral leishmaniasis in Brazil
spellingShingle The direct costs of treating human visceral leishmaniasis in Brazil
Assis, Tália Santana Machado de
terapeuticas
custos
analise de custos
leishmaniose visceral
Therapeutics
Costs
;; Cost analysis
Visceral leishmaniasis
title_short The direct costs of treating human visceral leishmaniasis in Brazil
title_full The direct costs of treating human visceral leishmaniasis in Brazil
title_fullStr The direct costs of treating human visceral leishmaniasis in Brazil
title_full_unstemmed The direct costs of treating human visceral leishmaniasis in Brazil
title_sort The direct costs of treating human visceral leishmaniasis in Brazil
author Assis, Tália Santana Machado de
author_facet Assis, Tália Santana Machado de
Rosa, Dian Carlos Pinheiro
Teixeira, Eliane de Morais
Cota, Gláucia Fernandes
Silva, André Luís Ferreira Azeredo da
Werneck, Guilherme
Rabello, Ana Lucia Teles
author_role author
author2 Rosa, Dian Carlos Pinheiro
Teixeira, Eliane de Morais
Cota, Gláucia Fernandes
Silva, André Luís Ferreira Azeredo da
Werneck, Guilherme
Rabello, Ana Lucia Teles
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Assis, Tália Santana Machado de
Rosa, Dian Carlos Pinheiro
Teixeira, Eliane de Morais
Cota, Gláucia Fernandes
Silva, André Luís Ferreira Azeredo da
Werneck, Guilherme
Rabello, Ana Lucia Teles
dc.subject.other.pt_BR.fl_str_mv terapeuticas
custos
analise de custos
leishmaniose visceral
topic terapeuticas
custos
analise de custos
leishmaniose visceral
Therapeutics
Costs
;; Cost analysis
Visceral leishmaniasis
dc.subject.en.pt_BR.fl_str_mv Therapeutics
Costs
;; Cost analysis
Visceral leishmaniasis
description Fundação Oswaldo Cruz. Instituto René Rachou. Pesquisa Clínica e Políticas Públicas em Doenças Infecciosas e Parasitárias. Belo Horizonte, MG, Brasil/Centro Federal de Educação Tecnológica de Minas Gerais. Contagem, MG, Brasil.
publishDate 2017
dc.date.issued.fl_str_mv 2017
dc.date.accessioned.fl_str_mv 2018-10-03T16:59:08Z
dc.date.available.fl_str_mv 2018-10-03T16:59:08Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv ASSIS, Tália Santana Machado de et al. The direct costs of treating human visceral leishmaniasis in Brazil. Rev. Soc. Bras. Med. Trop., v. 50, n. 4, p. 478-482, 2017
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/29297
dc.identifier.issn.pt_BR.fl_str_mv 0037-8682
dc.identifier.doi.none.fl_str_mv 10.1590/0037-8682-0133-2017
identifier_str_mv ASSIS, Tália Santana Machado de et al. The direct costs of treating human visceral leishmaniasis in Brazil. Rev. Soc. Bras. Med. Trop., v. 50, n. 4, p. 478-482, 2017
0037-8682
10.1590/0037-8682-0133-2017
url https://www.arca.fiocruz.br/handle/icict/29297
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Sociedade Brasileira de Medicina Tropical
publisher.none.fl_str_mv Sociedade Brasileira de Medicina Tropical
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/29297/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/29297/2/The%20direct%20costs%20of%20treating%20human%20visceral.pdf
https://www.arca.fiocruz.br/bitstream/icict/29297/3/The%20direct%20costs%20of%20treating%20human%20visceral.pdf.txt
bitstream.checksum.fl_str_mv 9193a7c197bc67acd023525e72a03240
70e43e776f164ae3ba77aa88ecd076c4
fef71bc1db09bcf4c61eae183cf30b34
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813008920694751232

Registros relacionados